DE60222135D1 - Tumorhemmende derivate von et-743 - Google Patents

Tumorhemmende derivate von et-743

Info

Publication number
DE60222135D1
DE60222135D1 DE60222135T DE60222135T DE60222135D1 DE 60222135 D1 DE60222135 D1 DE 60222135D1 DE 60222135 T DE60222135 T DE 60222135T DE 60222135 T DE60222135 T DE 60222135T DE 60222135 D1 DE60222135 D1 DE 60222135D1
Authority
DE
Germany
Prior art keywords
substituted
unsubstituted
alkenyl
alkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222135T
Other languages
English (en)
Other versions
DE60222135T2 (de
Inventor
Valentin Martinez
Maria Flores
Pilar Gallego
Carmen Cuevas
Simon Munt
Ignacio Manzanares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of DE60222135D1 publication Critical patent/DE60222135D1/de
Application granted granted Critical
Publication of DE60222135T2 publication Critical patent/DE60222135T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60222135T 2001-07-17 2002-07-17 Tumorhemmende derivate von et-743 Expired - Lifetime DE60222135T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0117402 2001-07-17
GBGB0117402.8A GB0117402D0 (en) 2001-07-17 2001-07-17 New antitumoral derivatives of et-743
PCT/GB2002/003288 WO2003008423A1 (en) 2001-07-17 2002-07-17 New antitumoral derivatives of et-743

Publications (2)

Publication Number Publication Date
DE60222135D1 true DE60222135D1 (de) 2007-10-11
DE60222135T2 DE60222135T2 (de) 2008-05-21

Family

ID=9918658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222135T Expired - Lifetime DE60222135T2 (de) 2001-07-17 2002-07-17 Tumorhemmende derivate von et-743

Country Status (16)

Country Link
US (2) US7759345B2 (de)
EP (3) EP2298780B1 (de)
JP (1) JP4653950B2 (de)
AT (1) ATE371661T1 (de)
AU (2) AU2002317967C1 (de)
CA (1) CA2453991C (de)
CY (2) CY1107809T1 (de)
DE (1) DE60222135T2 (de)
DK (3) DK1854800T3 (de)
ES (3) ES2389671T3 (de)
GB (1) GB0117402D0 (de)
MX (1) MXPA04000506A (de)
NO (2) NO335262B1 (de)
PT (3) PT1854800E (de)
SI (2) SI2298780T1 (de)
WO (1) WO2003008423A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
JP2008514688A (ja) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
GB0521536D0 (en) * 2005-10-22 2005-11-30 Invibio Ltd Fiducial marker
JP6037337B2 (ja) 2010-05-25 2016-12-07 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍｒｓ，Ｓ．Ａ． エクチナサイジン化合物の製造のための合成方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) * 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
HUP0104273A3 (en) 1998-04-06 2003-12-29 Univ Illinois Semi-synthetic ecteinascidins and pharmaceutical compositions containing them
ES2248999T3 (es) 1998-05-05 2006-03-16 Pharma Mar, S.A. Cultivo de animales marinos sesiles.
ATE289810T1 (de) 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
JP2003520801A (ja) 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
US6815544B2 (en) 2000-02-11 2004-11-09 President And Fellows Of Harvard College Synthetic process for an intermediate for ecteinascidin and phthalascidin compounds
US6569859B1 (en) 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
EP1280809B1 (de) 2000-04-12 2005-07-06 Pharma Mar, S.A. Ecteinaschidin derivate mit antikrebs wirkung
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
WO2002036135A2 (en) 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
WO2006005602A2 (en) 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
UA87877C2 (en) 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
PT1658848E (pt) 2004-10-29 2007-11-05 Pharma Mar Sa Formulações contendo ecteinascidina e um dissacarídeo
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007062413A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
CA2652035A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments
US20100267732A1 (en) 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
AU2009246130A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with PM00 104 and another antitumor agent
WO2009138509A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Multiple myeloma treatments

Also Published As

Publication number Publication date
DK1854800T3 (da) 2012-10-01
ES2394772T3 (es) 2013-02-05
ATE371661T1 (de) 2007-09-15
US20060106021A1 (en) 2006-05-18
EP2298780A1 (de) 2011-03-23
AU2008207381B2 (en) 2011-07-14
US20100197695A1 (en) 2010-08-05
GB0117402D0 (en) 2001-09-05
EP1854800A1 (de) 2007-11-14
US7759345B2 (en) 2010-07-20
DK2298780T3 (da) 2013-01-07
AU2008207381A1 (en) 2008-09-11
JP2004536132A (ja) 2004-12-02
EP2298780B1 (de) 2012-09-12
CA2453991A1 (en) 2003-01-30
AU2002317967C1 (en) 2009-01-22
DK1406907T3 (da) 2008-02-04
CY1113359T1 (el) 2016-06-22
PT1854800E (pt) 2012-09-25
NO340213B1 (no) 2017-03-20
NO20140711L (no) 2004-03-16
PT2298780E (pt) 2012-12-17
NO20040189L (no) 2004-03-16
CA2453991C (en) 2011-12-20
EP1406907A1 (de) 2004-04-14
PT1406907E (pt) 2007-12-10
US8076337B2 (en) 2011-12-13
ES2291479T3 (es) 2008-03-01
EP1406907B1 (de) 2007-08-29
EP1854800B1 (de) 2012-06-27
NO335262B1 (no) 2014-10-27
SI1854800T1 (sl) 2012-11-30
SI2298780T1 (sl) 2013-01-31
AU2002317967B2 (en) 2008-06-05
CY1107809T1 (el) 2013-06-19
JP4653950B2 (ja) 2011-03-16
MXPA04000506A (es) 2004-07-23
DE60222135T2 (de) 2008-05-21
ES2389671T3 (es) 2012-10-30
WO2003008423A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
CY1113359T1 (el) Αντι-νεοπλασιακα παραγωγα του et-743
DE60033857D1 (de) Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität
DK1117297T3 (da) Syntetiske analoger af ecteinascidin-743
MXPA04001240A (es) Analogos antitumorales.
PT1280809E (pt) Derivados antitumorais de ecteinascidina
DK1424330T3 (da) Aktivator for peroxisom proliferator-responsiv receptor delta
FI965020A0 (fi) Uusia yhdisteitä, menetelmiä niiden valmistamiseksi ja kasvaintenvastaisia aineita
DE60027131D1 (de) Inhibitoren für asparagin-proteasen
ATE232528T1 (de) Pyrimidinylpyrazolderivate
DE3474022D1 (de) Quinazoline and isoquinoline derivatives
HUP0200144A2 (hu) Eljárás peszticid hatású 5-amino-1-aril-3-cianopirazol-származékok előállítására és az új köztitermékek
FI894783A (fi) Substituerade aromatiska foereningar med verkan pao det centrala nervsystemet.
GB9012223D0 (en) Amines
GB0116966D0 (en) Anittumoral compounds

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: MARTINEZ, VALENTIN, TRES CANTOS, E-28760 MADRI, ES

Inventor name: FLORES, MARIA, TRES CANTOS, E-28760 MADRID, ES

Inventor name: GALLEGO, PILAR, TRES CANTOS, E-28760 MADRID, ES

Inventor name: CUEVAS, CARMEN, TRES CANTOS, E-28760 MADRID, ES

Inventor name: MUNT, SIMON, TRES CANTOS, E-28760 MADRID, ES

Inventor name: MANZANARES, IGNACIO, TRES CANTOS, E-28760 MADR, ES

8364 No opposition during term of opposition